Norges Bank’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-1,500,476
| Closed | -$28.3M | – | 2125 |
|
|
2019
Q3 | $28.3M | Buy |
1,500,476
+124,395
| +9% | +$1.42M | 0.01% | 1249 |
|
|
2019
Q2 | $16.2M | Sell |
1,376,081
-91,324
| -6% | -$1.11M | 0.01% | 1611 |
|
|
2019
Q1 | $20M | Buy |
1,467,405
+1,350,000
| +1,150% | +$17.5M | 0.01% | 1509 |
|
|
2018
Q4 | $1.2M | Hold |
117,405
| – | – | ﹤0.01% | 2032 |
|
|
2018
Q3 | $1.96M | Hold |
117,405
| – | – | ﹤0.01% | 2046 |
|
|
2018
Q2 | $1.85M | Hold |
117,405
| – | – | ﹤0.01% | 2032 |
|
|
2018
Q1 | $1.49M | Buy |
117,405
+72,260
| +160% | +$1.05M | ﹤0.01% | 2032 |
|
|
2017
Q4 | $517K | Hold |
45,145
| – | – | ﹤0.01% | 2090 |
|
|
2017
Q3 | $553K | Sell |
45,145
-125,034
| -73% | -$1.3M | ﹤0.01% | 2098 |
|
|
2017
Q2 | $1.95M | Sell |
170,179
-42,034
| -20% | -$777K | ﹤0.01% | 1992 |
|
|
2017
Q1 | $4.41M | Sell |
212,213
-49,940
| -19% | -$1.11M | ﹤0.01% | 1905 |
|
|
2016
Q4 | $5.45M | Hold |
262,153
| – | – | ﹤0.01% | 1848 |
|
|
2016
Q3 | $8.21M | Buy |
262,153
+41,845
| +19% | +$1.27M | ﹤0.01% | 1735 |
|
|
2016
Q2 | $5.5M | Sell |
220,308
-88,000
| -29% | -$2.38M | ﹤0.01% | 1849 |
|
|
2016
Q1 | $7.55M | Hold |
308,308
| – | – | ﹤0.01% | 1697 |
|
|
2015
Q4 | $10.2M | Buy |
308,308
+154,969
| +101% | +$5.24M | 0.01% | 1580 |
|
|
2015
Q3 | $5.02M | Buy |
+153,339
| New | +$6.52M | ﹤0.01% | 1844 |
|
Norges Bank's ALDR Position: Q4 2019 in Review
Norges Bank sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,500,476 shares — an estimated $28.3M sold.
Norges Bank first reported a position in ALDR in Q3 2015 and held it in 17 quarters. The position peaked at $28.3M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Norges Bank reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Norges Bank sold 1,500,476 Alder Biopharmaceuticals shares in Q4 2019, an estimated $28.3M.
- Norges Bank first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 17 quarters.
- Norges Bank's Alder Biopharmaceuticals position peaked at $28.3M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Norges Bank's 13F filing for Q4 2019, filed 12 Feb 2020.